Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) – Pipeline Review, H1 2018’, provides in depth analysis on Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Immunology, Infectious Disease, Metabolic Disorders and Respiratory under development targeting Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23)

– The report reviews Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics and enlists all their major and minor projects

– The report assesses Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Aurigene Discovery Technologies Ltd

Beta Pharma Inc

Cyclacel Pharmaceuticals Inc

Qurient Co Ltd

Syros Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC

2.7.11.22 or EC

2.7.11.23) Overview

Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC

2.7.11.22 or EC

2.7.11.23) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC

2.7.11.22 or EC

2.7.11.23) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC

2.7.11.22 or EC

2.7.11.23) Companies Involved in Therapeutics Development

Aurigene Discovery Technologies Ltd

Beta Pharma Inc

Cyclacel Pharmaceuticals Inc

Qurient Co Ltd

Syros Pharmaceuticals Inc

Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC

2.7.11.22 or EC

2.7.11.23) Drug Profiles

BS-181L Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CT-7001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sapacitabine + seliciclib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

seliciclib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK7 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK7 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK7 for Small Cell Lung Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Cyclin-Dependent Kinase 7 for Oncology, Inflammation and Infectious Diseases Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SY-1365 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TG-02 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC

2.7.11.22 or EC

2.7.11.23) Dormant Products

Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC

2.7.11.22 or EC

2.7.11.23) Discontinued Products

Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC

2.7.11.22 or EC

2.7.11.23) Product Development Milestones

Featured News & Press Releases

Dec 10, 2017: Syros Announces New Preclinical Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, Pointing to a Potential Biomarker of Response and Combination Approach

Dec 07, 2017: Syros Presents New Preclinical Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, and Discovery of Potential New Drug Targets in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium

Nov 30, 2017: Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of its Oral CDK7 Inhibitor: CT7001

Nov 13, 2017: Syros to Present New Preclinical Data on SY-1365 and on Identification of Potential Drug Targets in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium

Nov 01, 2017: Syros to Present New Preclinical Data on SY-1365 At ASH Annual Meeting

Oct 30, 2017: Syros Presents New Preclinical PK and PD Data for SY-1365, Its First-in-Class Selective CDK7 Inhibitor, at AACR-NCI-EORTC Conference

Oct 16, 2017: Syros to Present New Preclinical PK and PD Data on SY-1365, its First-in-Class Selective CDK7 Inhibitor, at AACR-NCI-EORTC Conference

May 15, 2017: Syros Announces First Patient Dosed in Phase 1 Clinical Trial of SY-1365, Its First-in-Class Selective CDK7 Inhibitor, in Patients with Advanced Solid Tumors

Apr 10, 2017: Syros Announces FDA Acceptance of IND to Advance SY-1365, Its First-in-Class Selective CDK7 Inhibitor, into Phase 1 Clinical Trial in Patients with Advanced Solid Tumors

Apr 03, 2017: Syros Presents New Preclinical Data at AACR Showing Anti-Tumor Activity of SY-1365, Its First-in-Class Selective CDK7 Inhibitor, in Multiple Difficult-to-Treat Solid Tumors

Mar 31, 2017: Aurigene to Present Data on CDK7 inhibitors program at the AACR 2017

Mar 01, 2017: Syros to Present New Data on SY-1365 at Upcoming AACR Annual Meeting

Feb 09, 2017: Syros Announces Publication in Cell Highlighting Gene Control as Important and Rapidly Progressing Area of Research for Yielding New Medicines to Treat Cancer

Jan 09, 2017: Syros Pharma Outlines 2017 Strategic Goals, Provides Update On SY-1365

Jun 10, 2016: Syros Pharmaceuticals Presents Data Demonstrating Significant Anti-Tumor Activity of its Lead Drug Candidate SY-1365 at 21st Congress of the European Hematology Association

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Aurigene Discovery Technologies Ltd, H1 2018

Pipeline by Beta Pharma Inc, H1 2018

Pipeline by Cyclacel Pharmaceuticals Inc, H1 2018

Pipeline by Qurient Co Ltd, H1 2018

Pipeline by Syros Pharmaceuticals Inc, H1 2018

Dormant Projects, H1 2018

Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports